Angela Meady often think about her grandmother and great-grandmother who did not accept barriers to their goals.

When I became converted in 1977 and began attending a non-denominational church, I was reminded that the evil forces were ...

Imagine for a moment a U.S. president continuously engaging biblical references to undergird a political agenda.

In the frost-bitten months of the year, function tends to take a backseat to fashion. The skies are gray, the ground is icy, ...

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Lexicon Pharmaceuticals LXRX in the last three months. The following table summarizes their ...

It's not the firmament described in the Bible, but it has its own beauty. Moreover, it's beautiful only because we can observe it as such. The universe simply is. That's it. But to paraphrase Carl ...

Lexicon (LXRX) announced that patient screening has been completed in the Phase 2b PROGRESS clinical trial evaluating the company’s AAK1 inhibitor, LX9211, for the treatment of Diabetic ...

Viatris expands its portfolio of cardiovascular disease treatments via licensing deal with Lexicon. Viatris has announced a licensing agreement with a Texas biopharm company for a drug that ...

The film itself created new movie tropes and set-piece techniques. Its terminology became a part of our lexicon. But beyond that, The Matrix *means* something. When you say, “The Matrix has you,” ...

Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...